Drugs / BMS-387032
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00446342 | Feb 2007 → Dec 2008 | B-cell chronic lymphocytic leukemia, mantle cell lymphoma, plasma cell myeloma | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00292864 | Jan 2006 → Dec 2007 | neoplasm | Sunesis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-387032 | ChEMBL registry synonym — accepted as the source's own label CHEMBL296468 ↗ |
| Known as | SNS-032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00292864 ↗ |
| Action | Inhibit | “SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor” NCT00292864 ↗3“Cyclin-dependent kinase 9 inhibitor” CHEMBL296468 ↗ “Cyclin-dependent kinase 2 inhibitor” CHEMBL296468 ↗ “Cyclin-dependent kinase 7 inhibitor” CHEMBL296468 ↗ |
| Modality | Small molecule | — CHEMBL296468 ↗ |
| Route | Intravenous | “one-hour infusions given once daily for 5 consecutive days” NCT00292864 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL296468 ↗ |
| Target | CDK7 | “Cyclin-dependent kinase 7 inhibitor” CHEMBL296468 ↗ |
| Target | CDK9 | “Cyclin-dependent kinase 9 inhibitor” CHEMBL296468 ↗ |